secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001193125-26-127783
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 1.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio approves spin-off of First Tracks Biotherapeutics; distribution set for April 20, 2026
--------------------------------------------------------------------------------

- Anaptys stockholders to receive one share of First Tracks Bio (TRAX) per ANAB share held on April 6, 2026; distribution expected pre-market April 20, 2026.
- First Tracks Bio launches with $180M cash ($100M from Anaptys + $80M from private placement at $13.81/share) and a two-year cash runway.
- Post-spin Anaptys to manage Jemperli (GSK) and imsidolimab (Vanda) royalties; virtual model with <10 FTEs and <$10M annual opex; $100M stock repurchase plan authorized.
- Susannah Gray (former Royalty Pharma CFO) appointed to Anaptys board; Dennis Mulroy and Eric Loumeau to exit with separation agreements.
- Anaptys terminates existing ATM sales agreement with TD Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526127783/0001193125-26-127783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526127783/d122216d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-127783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer